In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ProMetic BioTherapeutics Inc.

Division of Prometic Life Sciences Inc.

Latest From ProMetic BioTherapeutics Inc.

AM-Pharma BV

AM-Pharma BV, a Dutch start up firm, is trying to harness the body's innate ability to fight infection. The company has three programs based on its antimicrobial peptide technology platform and has recently merged with compatriot PharmAAware Sepsis BV to pursue the use of alkaline phosphatase as a treatment for sepsis and other infection-inspired inflammatory disorders.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • ProMetic BioSciences Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Prometic Life Sciences Inc.
  • Senior Management
  • Steve Burton, PhD, Pres. & CEO
    Peter Bonnett, VP, Sales & Mktg.
  • Contact Info
  • ProMetic BioTherapeutics Inc.
    Phone: (450) 781-1394
    500 Cartier West Blvd.
    Ste. 150
    Laval, H7V 5B7